Logo image of CUTR

CUTERA INC (CUTR) Stock Fundamental Analysis

NASDAQ:CUTR - Nasdaq - US2321091082 - Common Stock - Currency: USD

0.0969  -0.01 (-10.19%)

After market: 0.0381 -0.06 (-60.68%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CUTR. CUTR was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CUTR have multiple concerns. CUTR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CUTR has reported negative net income.
CUTR had a negative operating cash flow in the past year.
In the past 5 years CUTR reported 4 times negative net income.
In the past 5 years CUTR reported 4 times negative operating cash flow.
CUTR Yearly Net Income VS EBIT VS OCF VS FCFCUTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -61.31%, CUTR is not doing good in the industry: 73.02% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -61.31%
ROE N/A
ROIC N/A
ROA(3y)-20.69%
ROA(5y)-18.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CUTR Yearly ROA, ROE, ROICCUTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

With a Gross Margin value of 5.93%, CUTR is not doing good in the industry: 82.01% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of CUTR has declined.
CUTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.52%
GM growth 5Y-16.94%
CUTR Yearly Profit, Operating, Gross MarginsCUTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

CUTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
CUTR has more shares outstanding than it did 1 year ago.
CUTR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CUTR is higher compared to a year ago.
CUTR Yearly Shares OutstandingCUTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
CUTR Yearly Total Debt VS Total AssetsCUTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.16, we must say that CUTR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.16, CUTR is not doing good in the industry: 64.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC2.27%
CUTR Yearly LT Debt VS Equity VS FCFCUTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.88 indicates that CUTR has no problem at all paying its short term obligations.
CUTR has a Current ratio (2.88) which is in line with its industry peers.
A Quick Ratio of 1.86 indicates that CUTR should not have too much problems paying its short term obligations.
CUTR has a Quick ratio (1.86) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 1.86
CUTR Yearly Current Assets VS Current LiabilitesCUTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

2

3. Growth

3.1 Past

CUTR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.75%.
CUTR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.53%.
Measured over the past years, CUTR shows a small growth in Revenue. The Revenue has been growing by 5.47% on average per year.
EPS 1Y (TTM)-53.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.73%
Revenue 1Y (TTM)-32.53%
Revenue growth 3Y12.87%
Revenue growth 5Y5.47%
Sales Q2Q%-30.07%

3.2 Future

The Earnings Per Share is expected to grow by 10.52% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.29% on average over the next years.
EPS Next Y-15.64%
EPS Next 2Y12.13%
EPS Next 3Y12.16%
EPS Next 5Y10.52%
Revenue Next Year-32.88%
Revenue Next 2Y-16.2%
Revenue Next 3Y-7.65%
Revenue Next 5Y4.29%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CUTR Yearly Revenue VS EstimatesCUTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CUTR Yearly EPS VS EstimatesCUTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CUTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUTR Price Earnings VS Forward Price EarningsCUTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUTR Per share dataCUTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

CUTR's earnings are expected to grow with 12.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.13%
EPS Next 3Y12.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CUTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUTERA INC

NASDAQ:CUTR (3/12/2025, 8:00:00 PM)

After market: 0.0381 -0.06 (-60.68%)

0.0969

-0.01 (-10.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners33.67%
Inst Owner Change-0.24%
Ins Owners0.61%
Ins Owner Change-0.27%
Market Cap1.96M
Analysts80
Price Target2.04 (2005.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.13%
Min EPS beat(2)-70.55%
Max EPS beat(2)-21.7%
EPS beat(4)1
Avg EPS beat(4)-25.35%
Min EPS beat(4)-70.55%
Max EPS beat(4)31.14%
EPS beat(8)2
Avg EPS beat(8)-27.63%
EPS beat(12)3
Avg EPS beat(12)-73.2%
EPS beat(16)7
Avg EPS beat(16)33.41%
Revenue beat(2)0
Avg Revenue beat(2)-6.8%
Min Revenue beat(2)-12.9%
Max Revenue beat(2)-0.69%
Revenue beat(4)2
Avg Revenue beat(4)-2.36%
Min Revenue beat(4)-12.9%
Max Revenue beat(4)2.25%
Revenue beat(8)2
Avg Revenue beat(8)-4.68%
Revenue beat(12)3
Avg Revenue beat(12)-2.87%
Revenue beat(16)7
Avg Revenue beat(16)1.32%
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)9.18%
EPS NQ rev (3m)9.18%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.92
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-5.96
FCFYN/A
OCF(TTM)-5.78
OCFYN/A
SpS7.69
BVpS-12.52
TBVpS-12.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.93%
FCFM N/A
ROA(3y)-20.69%
ROA(5y)-18.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.52%
GM growth 5Y-16.94%
F-Score2
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.64%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 1.86
Altman-Z -3.16
F-Score2
WACC2.27%
ROIC/WACCN/A
Cap/Depr(3y)442.5%
Cap/Depr(5y)296.69%
Cap/Sales(3y)8.33%
Cap/Sales(5y)5.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.73%
EPS Next Y-15.64%
EPS Next 2Y12.13%
EPS Next 3Y12.16%
EPS Next 5Y10.52%
Revenue 1Y (TTM)-32.53%
Revenue growth 3Y12.87%
Revenue growth 5Y5.47%
Sales Q2Q%-30.07%
Revenue Next Year-32.88%
Revenue Next 2Y-16.2%
Revenue Next 3Y-7.65%
Revenue Next 5Y4.29%
EBIT growth 1Y-45.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.52%
EBIT Next 3Y16.97%
EBIT Next 5Y15.93%
FCF growth 1Y-94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.55%
OCF growth 3YN/A
OCF growth 5YN/A